Cerebral ischemia is an acute disorder characterized by an abrupt reduction in blood flow that results in immediate deprivation of both glucose and oxygen. The main types of cerebral ischemia are ischemic and hemorrhagic ...

Antibody–drug conjugates (ADCs) are relatively newly developed treatments but rapidly growing science. Theoretically, they are like a combination of payload (the drug that is to be delivered; often cytotoxic) and targeted ...

The present study was designed to investigate the effect of cyclosporine on hyperglycemia induced decrease antinociceptive effect of morphine in rats. Streptozotocin (STZ) (50 mg kg-1, i.p., once) was administered to induce ...

Early detection, prognosis, and diagnosis of devastating neurological disorders such as TBI and AD are crucial for developing treatment strategies, efficient patient outcomes, and management in biomedical fields. The work ...

Multiple biological barriers and discrepancy in releasing the optimal dosage range pose a great challenge in the current therapeutic management for majority of diseases. Nanoparticle drug delivery system (5–250 nm) possesses ...

Chitinase-3-like-1 (CHI3L1) is an evolutionarily conserved protein involved in key biological processes, including tissue remodeling, angiogenesis, and neuroinflammation. It has emerged as a significant player in various ...

Parkinson’s disease is the second most prevalent neurological disease after Alzheimer’s. Primarily, old age males are more affected than females. The aggregates of oligomeric forms of α-synuclein cause the loss of dopaminergic ...

Diabetes mellitus is a metabolic disorder characterized by inadequate insulin secretion and signaling dysfunction, leading to a vast spectrum of systemic complications. These complications trigger cascades of events that ...

2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a is a second-generation, lipophilic, chlorin-based photosensitizer currently used for various types of solid cancer including breast, esophageal, neck, and head cancer, etc. ...

Repaglinide (REP) an insulinotropic agent used in the treatment of type-2 diabetes. It belongs to meglitinides, which act by blocking the ATP sensitive potassium channels and stimulates the insulin release. REP is the first ...